Abstract

<p dir="ltr"><i>Objectives:</i> <a href="" target="_blank">The hyperosmolar hyperglycemic state</a> (HHS) is a rare and life-threatening complication of diabetes. We aimed to estimate the incidence of HHS and describe the clinical and biomarker profiles of patients with HHS, including subgroups with acidosis and acute kidney injury.</p><p dir="ltr"><i>Methods:</i> This nationwide descriptive cohort study used Danish registry data during years 2016–2018 to identify acutely admitted patients fulfilling the hyperglycemia and hyperosmolarity criteria of HHS (glucose ≥33 mmol/L and osmolarity (2 x sodium + glucose) ≥320 mmol/L).</p><p dir="ltr"><i>Results:</i> We identified 634 patients with a median age of 69 years (Q1;Q3: 58;79) who met the criteria of HHS among 4.80 million inhabitants of age ≥18 years. The incidence rates were 16.5 and 3.9 per 10,000 person-years among persons with known type 1 (n=24,196) and 2 diabetes (n=251,357), respectively. Thirty-two percent of patients with HHS were not previously diagnosed with diabetes. Patients were categorized as pure HHS (n=394) and combined HHS and diabetic ketoacidosis (DKA) (n=240). The in-hospital mortality for pure HHS was 17% and 9% for HHS-DKA.</p><p dir="ltr"><i>Conclusions:</i> The incidence rate of HHS was higher among patients with type 1 diabetes compared with type 2 diabetes. HHS is a spectrum of hyperglycemic crises and can be divided in pure HHS and HHS-DKA. In one third of the patients, HHS was the debut of their diabetes diagnosis.</p>

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call